Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 6, 2006, Pages 2205-2208

  Ghori, Farah ^a   Polder, Kristel D ^b   Pinter Brown, Lauren C ^c   Hoff, Ana O ^a   Gagel, Robert F ^a   Sherman, Steven I ^a   Duvic, Madeleine ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Health Science Center at Houston   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENILEUKIN DIFTITOX; LIOTRIX;

ADULT; AGED; ANAPHYLAXIS; ANEMIA; ARTICLE; CANCER CENTER; CANCER PATIENT; CHILL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DIARRHEA; DISEASE ASSOCIATION; EDEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPOTENSION; HYPOTHYROIDISM; LABORATORY TEST; LEUKOPENIA; MALE; MYCOSIS FUNGOIDES; NAUSEA AND VOMITING; NERVOUSNESS; ONSET AGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; THYROID FUNCTION TEST; THYROTOXICOSIS; TREMOR; VASCULAR DISEASE; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; FEMALE; HUMANS; INTERLEUKIN-2; IODIDE PEROXIDASE; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; THYROTOXICOSIS;

EID: 33744954162     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2839     Document Type: Article

References (24)

1. 486-IL-2). Fragment B sequences required for delivery of fragment A to the cytosol of target cells. J Biol Chem 265:11885-11889
2. Lowenthal JW, Zubler RH, Nabholz M, MacDonald HR 1985 Similarities between interleukin-2 receptor numbers and affinity on activated B and T lymphocytes. Nature 315:669-672
3. Nichols J, Foss F, Kuzel TM, LeMaistre CF, Platanias L, Ratain MJ, Rook A, Saleh M, Schwartz G 1997 Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Euro J Cancer 33:S34-S36
4. LeMaistre CF, Saleh MN, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Nichols JC 1998 Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 91:399-405
5. 389IL-2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T-cell lymphoma. Am J Hematol 58:87-90
6. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J 2001 Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376-388
7. Walker P, Dang NH 2004 Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma. Clin J Oncol Nurs 8:169-174
8. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L 2004 Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 22:4095-4102
9. Martin A, Gutierrez E, Muglia J, McDonald CJ, Guzzo C, Gottlieb A, Pappert A, Garland WT, Bagel J, Bacha P 2001 A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis. J Am Acad Dermatol 45:871-881
10. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C, Steckel S, Cutler C, Fisher DC, Lee SJ, Alyea EP, Ritz J, Soiffer RJ, Antin JH 2004 Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoetic stem cell transplantation. Blood 104:1224-1226
11. Shaughnessy PJ, Bachier C, Grimley M, Freytes CO, Callander NS, Essell JH, Flomenberg N, Selby G, Lemaistre CF 2005 Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Bone Marrow Transplant 11:188-193
12. Frankel AE, Fleming DR, Hall PD, Powell BL, Black JH, Leftwich C, Gartenhaus R 2003 A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res 9:3555-3561
13. Eklund JW, Kuzel TM 2005 Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther 5:33-38
14. Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R 2003 Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 49:35-49
15. Krouse RS, Royal RE, Heywood G, Weintraub BD, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ 1995 Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin alone. J Immunother 18:272-278
16. Sellin RV, Sella A, Dexeus FH, Theriault RL, Pololoff DA 1992 Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2. Horm Metab Res 24:434-438
17. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM 1988 Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318:1557-1563
18. Sauter NP, Atkins MB, Mier JW, Lechan RM 1992 Transient thyrotoxicosis and persistent hypothyroidism due to an autoimmune thyroiditis after interleukin-2 and interferon-α therapy for metastatic carcinoma: a case report. Am J Med 92:441-444
19. Abad S, Blanche P, Moachon L, Brunet A, Héripret-Fredouille L, Sicard D, Salmon-Ceron D 2002 Unusual thyroiditis after recombinant interleukin-2 therapy. Int J STD AIDS 13:790-791
20. Badami E, Maiuri L, Quaratino S 2005 High incidence of spontaneous autoimmune thyroiditis in immunocompetent self-reactive human T cell receptor transgenic mice. J Autoimmun 2:85-91
21. Aiello A, Cristofaro M, Carrozza F, Verdone F, Carile L 1990 Lymphocyte subpopulations and the soluble interleukin-2 receptor in Hashimoto's thyroiditis and subacute thyroiditis. Clin Ter 133:401-404
22. Jackow CM, McHam JB, Friss A, Alvear J, Reveille JR, Duvic M 1996 HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma. J Invest Dermatol 107:373-376
23. Schuppert F, Rambusch E, Kirchner H, Atzpodien J, Kohn LD, Von Zur Muhlen A 1997 Patients treated with interferon-α, interferon-β, and interleukin-2 have a different thyroid autoantibody pattern than patients suffering from endogenous autoimmune thyroid disease. Thyroid 7:837-842
24. Pearce EN, Farwell AP, Braverman LE 2003 Review article: thyroiditis. N Engl J Med 348:2646-2655